CHICAGO & TEMECULA, Calif.--(BUSINESS WIRE)--CytoCore, Inc. (OTCBB:CYTO), the developer of cost effective products used for the detection of cancerous and precancerous conditions and privately held Zycom Touch, LLC., today announced that they have reached an agreement in principle for CytoCore to distribute OmniDROP™ on an exclusive basis to medical laboratories, hospitals, and HMO networks in the U.S. and non-exclusively internationally.
